On October 23, 2026 Tempus AI, Inc. (NASDAQ: TEM, "Tempus") reported a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train and execute advanced AI models using de-identified data to surface breakthroughs faster and increase the probability of technical success when developing candidate therapies at scale.
This agreement expands upon the long-standing strategic relationship between Tempus and BMS, which includes applying AI and multimodal real-world data to optimize clinical trial design across high-priority oncology programs and neuroscience initiatives.
"This strategic collaboration is an important step forward in using AI to advance the discovery of new treatment options and potentially improve patient outcomes," said Eric Lefkofsky, Founder and CEO of Tempus. "By uniting our vast multimodal data asset with dedicated GPU power inside our Lens Platform, we are equipping BMS with the AI tools necessary to decode complex biology. Together, we aren’t just speeding up drug discovery, we are laying the foundation for a future where precision oncology becomes the standard of care for every patient."
(Press release, Tempus, OCT 23, 2026, View Source [SID1234673744])